Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer [Phase 2]
Phase 2 study of DRP-104 in patients with NFE2L2/KEAP1-altered non-small cell lung cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies [NA]
Clinical trial update on real-time symptom monitoring in lung cancer patients receiving oral targeted therapies, including EGFR-mutant and o…
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
A completed ClinicalTrials.gov study evaluating nivolumab in patients with advanced non-small cell lung cancer in France after prior chemoth…
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus
This completed clinical trial evaluated nivolumab for locally advanced or metastatic non-small cell lung cancer in patients previously treat…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC [Phase 1]
Phase 1 trial evaluating LB-LR1109 alone and in combination with atezolizumab for solid tumors, including non-small cell lung cancer, curren…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
This clinical trial update describes a flow cytometry-based neutrophil biomarker test intended to predict clinical benefit from immunotherap…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors [Phase 1]
Phase 1 study evaluating CLN-619 alone and in combination with pembrolizumab in advanced solid tumors, including non-small cell lung cancer.
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Is 3D Modeling From Non-contrast CT Accurate for Minimally Invasive Lung Segmentectomies ?
An updated clinical trial from University Hospital, Strasbourg evaluates whether three-dimensional modeling derived from non-contrast CT sca…
-
CLINICAL_TRIALS other · 2025-11-24Clinical Trial Update: Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating Sac-TMT in combination with bevacizumab as second-line treatment for advanced non-squamous non-small cell lung canc…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors [Phase 1]
This clinical trial update reports a Phase 1 study of BL-M24D1 in locally advanced or metastatic non-small cell lung cancer and other solid …
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: Multimodal Model Predicts Treatment Efficacy and CIP Risk in Advanced NSCLC With Immunotherapy and Chemotherapy
A completed clinical trial evaluating a multimodal model that predicts treatment efficacy and the risk of checkpoint inhibitor pneumonitis i…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Patient-centered, Optimal Integration of Survivorship and Palliative Care [NA]
A Massachusetts General Hospital trial is recruiting to evaluate patient-centered integration of survivorship and palliative care for patien…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: A Study of GV20-0251 in Advanced or Refractory Solid Tumors [Phase 1]
This Phase 1 clinical trial update indicates that GV20-0251 is being studied in advanced or refractory solid tumors and is currently recruit…
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. [Phase 2, Phase 3]
Phase 2/3 DETERMINE trial treatment arm 05 is evaluating the combination of vemurafenib and cobimetinib in adults with BRAF-positive cancers…
-
EMA approval · 2025-11-21EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Yervoy (ipilimumab) for multiple cancer indications. It lists melanoma, renal cell carcinoma, non-s…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) [Phase 3]
Phase 3 TRIDENT-3 trial comparing repotrectinib versus crizotinib in treatment-naïve ROS1-positive non-small cell lung cancer; the study is …
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors [Phase 1]
Phase 1 study evaluating CFT1946 as monotherapy and in combination for BRAF V600-mutant solid tumors to assess safety, tolerability, and pre…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors [Phase 1]
This is a Phase 1 clinical trial update for HiFiBiO's HFB200301 as a single agent and in combination with tislelizumab in adults with advanc…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors [Phase 1]
Phase 1 study of HFB200603 as a single agent and in combination with tislelizumab in adults with advanced solid tumors, including renal cell…
-
CLINICAL_TRIALS withdrawal · 2025-11-21Clinical Trial Update: A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 trial evaluating BT-001 alone and in combination with pembrolizumab in metastatic or advanced solid tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial [NA]
Completed clinical trial evaluating a supportive care intervention (ROAR-LCT) for patients with advanced non-small cell lung cancer and smal…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC [Phase 3]
Phase 3 trial comparing JMKX001899 to docetaxel in previously treated KRAS G12C-mutant non-small cell lung cancer is not yet recruiting.
-
CLINICAL_TRIALS other · 2025-11-21Clinical Trial Update: High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI [Phase 2]
A Phase 2 clinical trial evaluating high-dose furmonertinib alone or in combination with chemotherapy in EGFR-mutant advanced non-small cell…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer [Phase 2]
Phase 2 study evaluating Ivonescimab as a standalone treatment or with chemotherapy as neoadjuvant/adjuvant therapy for resectable non-small…
-
FDA approval · 2025-11-20FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for RETEVMO (selpercatinib) submitted by Eli Lilly and Company, expanding its approved indicatio…